Poly Medicure
Market cap ₹16,770 Cr
- P/E
- 52.74
- Day range
- ₹1,640.10 – ₹1,686.20
- 52-week range
- ₹1,182.00 – ₹2,024.00
- Volume
- 55,639
- Open
- ₹1,640.10
- Prev close
- ₹1,649.60
Latest results · Q2 FY27(consolidated)Revenue ₹581 Cr+30.8%Profit ₹95 Cr+3.6%Margin 16.4%YoY vs the same quarter last year
No red flags in exchange filings: no rising pledge, promoter selling, surveillance or critical filing on record.
POLYMED in NSE indices and F&O
Research profile
Composite 43 / 100Factor percentiles
Derived metrics
- Earn. yield
- 1.9%
- Graham no.
- ₹471.15
- vs Graham
- -71.5%
- ROE ÷ P/B
- 2.1%
- 12-1 mom.
- -14.4%
- Return / vol
- -0.27
- Magic Formula
- #514
- Piotroski
- 2/6
- FCF yield
- -0.4%
- PEG
- 14.55
Appears in 7 scans
Percentiles rank this stock against the other tracked stocks and change as they do. Scans describe where figures sit today. Hover a label for its definition. Not investment advice.
Peer comparison
All 68 in Pharma| Company | M-cap | P/E | P/B | ROE | ROCE | OPM | D/E | Sales YoY |
|---|---|---|---|---|---|---|---|---|
| Sun PharmaSUNPHARMA | ₹4.49 L Cr | 40.95 | 5.03 | 14.8% | 21.0% | 29.0% | 0.04 | +11.9% |
| Divi's LaboratoriesDIVISLAB | ₹2.93 L Cr | 87.19 | 16.88 | 16.2% | 22.0% | 43.0% | 0.00 | +35.4% |
| Torrent PharmaTORNTPHARM | ₹1.75 L Cr | 77.88 | 9.67 | 26.8% | 15.0% | 33.0% | 0.77 | +50.8% |
| Apollo HospitalsAPOLLOHOSP | ₹1.27 L Cr | 56.40 | 11.55 | 22.6% | 17.0% | 16.0% | 0.77 | +23.0% |
| Laurus LabsLAURUSLABS | ₹1.25 L Cr | 93.72 | 19.82 | 18.2% | 18.0% | 34.0% | 0.43 | +33.5% |
| Zydus LifesciencesZYDUSLIFE | ₹1.20 L Cr | 28.72 | 4.32 | 20.1% | 21.0% | 24.0% | 0.50 | +29.2% |
| Dr. Reddy's LabsDRREDDY | ₹1.17 L Cr | 41.63 | 2.97 | 11.6% | 13.0% | 20.0% | 0.19 | -1.5% |
| Poly MedicurePOLYMED | ₹16,770 Cr | 52.74 | 5.23 | 10.9% | 12.0% | 24.0% | 0.13 | +30.9% |
| Sector median | ₹24,603 Cr | 43.68 | 5.46 | 15.1% | 17.0% | 24.0% | 0.17 | +22.7% |
Sector as classified in the tracked universe; medians use every tracked Pharma company, and P/E only profitable ones. Tinted figures beat the median.
Latest news
Updated 1h agoHeadlines about Poly Medicure from the last two weeks in the financial press. Stories belong to their publishers; Rajat Finance does not endorse them.
Key metrics
- P/E (TTM)
- 54.0
- Price / Book
- 5.14
- ROE (FY26)
- 10.9%
- ROCE (latest year)
- 12%
- Dividend yield
- 0.21%
Moving averages (NSE)
- 20-day
- ₹1,554.94
- Price above
- 50-day
- ₹1,621.51
- Price above
- 200-day
- ₹1,546.84
- Price above
Charts & trends
From company filings. Amounts in ₹ crore.
Revenue, profit & margin - quarterly
₹ crore; a loss shows red. Operating margin below, same periods.
- Revenue
- Net profit
Operating margin
Who owns the company
% of equity by quarter, latest Sept 2026
- Promoter
- Public
- DII
- FII
Cash flows
Where cash came from and went, by fiscal year (₹ crore)
- Operating
- Investing
- Financing
- Free cash flow
Return on equity
Net profit over shareholders' equity, by fiscal year
Equity vs debt
Shareholders' equity against borrowings (₹ crore); the ratio below, same years.
- Equity
- Debt
Debt to equity
Dividends per share
₹ by fiscal year of the ex-date; the latest year runs to date.
Financial statements
| Line item | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 340 | 378 | 385 | 420 | 424 | 441 | 403 | 444 | 494 | 535 | 525 | 581 |
| Expenses | 249 | 282 | 281 | 305 | 310 | 321 | 298 | 329 | 382 | 424 | 400 | 443 |
| Operating Profit | 90 | 96 | 104 | 115 | 114 | 119 | 106 | 115 | 111 | 110 | 125 | 138 |
| OPM % | 27% | 26% | 27% | 27% | 27% | 27% | 26% | 26% | 23% | 21% | 24% | 24% |
| Other Income | 17 | 15 | 17 | 27 | 24 | 27 | 43 | 35 | 21 | 19 | 35 | 30 |
| Interest | 3 | 3 | 3 | 3 | 3 | 2 | 3 | 3 | 6 | 6 | 6 | 7 |
| Depreciation | 16 | 16 | 20 | 21 | 21 | 21 | 23 | 25 | 29 | 38 | 36 | 35 |
| Profit before tax | 88 | 92 | 98 | 118 | 113 | 123 | 123 | 122 | 98 | 85 | 117 | 125 |
| Tax % | 26% | 26% | 25% | 26% | 25% | 25% | 24% | 25% | 27% | 24% | 27% | 24% |
| Net Profit | 65 | 68 | 74 | 87 | 85 | 92 | 93 | 92 | 71 | 65 | 85 | 95 |
| EPS in Rs | ₹6.78 | ₹7.12 | ₹7.71 | ₹8.63 | ₹8.41 | ₹9.06 | ₹9.19 | ₹9.06 | ₹7.00 | ₹6.54 | ₹8.49 | ₹9.39 |
From company filings, updated 17 Nov 2026. Consolidated figures where the company reports them. Information only, not investment advice.
Working-capital cycle
+31 days since Mar 2021
+106 days since Mar 2021
-20 days since Mar 2021
+156 days since Mar 2021
+31 days since Mar 2021
Strengths, risks & growth
Poly Medicure Limited is an India-based manufacturer and exporter of medical devices. The Company exports plastic medical disposables/surgical devices. [1]
Strengths
None flagged by the checklist.
Risks
- Company has a low return on equity of 13.3% over last 3 years.
- Debtor days have increased from 83.9 to 103 days.
Compounded Sales Growth
- 10 Years
- +16%
- 5 Years
- +19%
- 3 Years
- +19%
- TTM
- +25%
Compounded Profit Growth
- 10 Years
- +20%
- 5 Years
- +16%
- 3 Years
- +19%
- TTM
- -13%
Stock Price CAGR
- 10 Years
- +25%
- 5 Years
- +13%
- 3 Years
- +3%
- 1 Year
- -13%
Return on Equity
- 10 Years
- +15%
- 5 Years
- +14%
- 3 Years
- +13%
- Last Year
- +10%
Strengths and risks are a machine-generated checklist, not advice; growth is compounded annually over each period.
Shareholding pattern
| Holder | Dec 2025 | Mar 2026 | Jun 2026 | Sept 2026 | Change |
|---|---|---|---|---|---|
| Promoter | 62.42% | 62.42% | 62.42% | 62.41% | -0.01 pp |
| FII | 9.41% | 5.92% | 5.56% | 5.36% | -0.20 pp |
| DII | 13.84% | 15.60% | 16.08% | 15.90% | -0.18 pp |
| Public | 14.34% | 16.08% | 15.94% | 16.33% | +0.39 pp |
Filed with NSE for Sept 2026: promoters 62.42%, public 37.58%
Analysts & fund holdings
Who holds the shares, quarter by quarter
Mutual funds 9.77% (+0.16 pp)- Promoters62.4%
- Foreign institutions5.3%
- Mutual funds9.8%
- Insurance2.3%
- Other domestic institutions3.8%
- Retail7.7%
- Others8.6%
| Fund | % of company | % of fund | 3-month change |
|---|---|---|---|
| Quant Small Cap Fund | 3.78% | 1.87% | -0.31 pp |
| UTI Flexi Cap Fund | 1.18% | 0.88% | -0.11 pp |
| HSBC Midcap Fund | 1.07% | 1.07% | +0.11 pp |
| SBI Healthcare Opp Fund | 0.54% | 1.53% | -0.49 pp |
| SBI MNC Fund | 0.52% | 1.42% | -0.05 pp |
Scorecard
- Performance
- Low
- Valuation
- High
- Growth
- Avg
- Profitability
- High
- Entry point
- Good
- Red flags
- Low
Analyst coverage, holdings and scorecard from market data; not a recommendation by Rajat Finance.
Risk & trend
From 292 daily sessions to 18 Nov 2026.
Risk
- Volatility (1Y)
- 41.4%
- Downside volatility
- 38.1%
- Worst 5% of days
- 4.5%
- Average of that tail
- 5.7%
- Max drawdown (1Y)
- 42.3%
- Below its peak
- 19.9%
Against the market
- Beta vs Nifty 50
- 0.89
- Correlation
- 0.29
- Relative strength (3M)
- -8.4%
- ATR (14)
- 3.3%
Return
- Return 1M
- +3.8%
- Return 3M
- -4.6%
- Return 6M
- +13.9%
- Return 1Y
- -11.2%
- vs 200-day average
- +7.0%
Momentum
- RSI (14)
- 58.9
- MACD histogram
- 19.68
- Stochastic %K
- 81.3
- ADX (14)
- 26.3
- +DI / −DI
- 22.8 / 15.9
- Money flow index
- 74.3
Participation
- Delivery (20d avg)
- 49.7%
- vs its 60-day baseline
- +1.4 pts
- Volume vs 20-day
- -0.5σ
- Close vs day's VWAP
- -0.6%
- 52-week position
- 53 / 100
These describe what this stock's price has already done. They are not forecasts, signals or recommendations, and a dash means the figure was withheld for want of enough history rather than being zero.
Financial quality
From consolidated statements to 30 Sept 2026.
Piotroski F-Score
2 of 6 tested
- Return on assets positive — passed
- Operating cash flow positive — not testableno cash flow statement for this period
- Return on assets improving — failed
- Cash flow exceeds profit — not testableneeds cash flow and profit against assets
- Debt to assets falling — failed
- Current ratio improving — failed
- No new equity issued — not testableno share count is collected, and financing cash flow mixes equity with debt
- Operating margin improving — failed
- Asset turnover improving — passed
- Free cash flow
- -₹62 Cr
- FCF yield
- -0.4%
- Cash conversion
- 0.77
- Accruals ratio
- 0.019
- Net debt
- ₹354 Cr
- Net debt / equity
- 0.11
- EV / sales
- 8.02
- PEG
- 14.55
- Capex intensity
- 16.4%
- Revenue CAGR
- 20.1%
- Profit CAGR
- 2.4%
Computed from filed statements, not filed themselves. A dash means an input was absent, and the score counts only the criteria that could actually be tested.
Corporate actions
- dividend₹3.50
Dividend - Rs 3.50 Per Share
28 Aug 2026ex-date - dividend₹3.50
Dividend - Rs 3.50 Per Share
18 Sept 2025ex-date - dividend₹3.00
Annual General Meeting/Dividend - Rs 3 Per Share
19 Sept 2024ex-date - dividend₹3.00
Annual General Meeting/Dividend - Rs 3 Per Share
21 Sept 2023ex-date - dividend₹2.50
Annual General Meeting/Dividend - Rs 2.50 Per Share
16 Sept 2022ex-date - otherNot available — not reported in this filing
Annual General Meeting
16 Sept 2021ex-date - dividend₹2.50
Dividend - Rs 2.50 Per Share
16 Sept 2021ex-date - otherNot available — not reported in this filing
Annual General Meeting
21 Sept 2020ex-date - dividend₹2.00
Interim Dividend - Rs 2 Per Share
27 Feb 2020ex-date - dividend₹2.00
Annual General Meeting/Dividend - Rs 2 Per Share
13 Sept 2019ex-date - dividend₹2.00
Annual General Meeting/Dividend- Rs 2 Per Share (Purpose Revised)
18 Sept 2018ex-date - dividendNot available — not reported in this filing
Dividend- Re 0.50 Per Share
20 Sept 2017ex-date - dividendNot available — not reported in this filing
Annual General Meeting/Dividend - Re 0.50 Per Share
20 Sept 2017ex-date - bonusNot available — not reported in this filing
Bonus 1:1
24 Mar 2017ex-date - dividendNot available — not reported in this filing
Interim Dividend Re 1/- Per Share
15 Feb 2017ex-date - dividendNot available — not reported in this filing
Interim Dividend Re 1/- Per Share (Purpose Revised)
11 Nov 2016ex-date - dividendNot available — not reported in this filing
Annual General Meeting/Dividend - Re 0.50 Per Share (Purpose Revised)
19 Sept 2016ex-date - dividend₹2.50
Interim Dividend - Rs 2.50/- Per Share (Purpose Revised)
17 Mar 2016ex-date - dividend₹2.50
Annual General Meeting/Dividend Rs 2.50 Per Share
18 Sept 2015ex-date - splitNot available — not reported in this filing
Face Value Split (Sub-Division) - From Rs 10/- Per Share To Rs 5/- Per Share
2 Feb 2015ex-date
Company announcements
Please find enclosed Certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018
The Company Informed the Exchange about the Closure of Trading Window.
Enclosed
Enclosed
Enclosed
Enclosed
Scrutinizer Report and Voting Results
Outcome of the 31st Annual General Meeting of the Poly Medicure Limited.
Enclosed
Enclosed
Enclosed
Enclosed
Enclosed
Copy of the news paper publication
Enclosed
Filed with BSE (scrip 531768); the last 45 days. Documents open at bseindia.com.
Documents
Annual reports
Earnings calls
- Nov 2026TranscriptSlidesRecording
- Aug 2026TranscriptSlidesRecording
- May 2026TranscriptSlidesRecording
- May 2026Slides
- Mar 2026TranscriptSlidesRecording
- Feb 2026Slides
Credit ratings
- Rating update · 24 Jun from crisil
- Rating update · 31 Mar 2025 from crisil
- Rating update · 29 Mar 2025 from crisil
- Rating update · 29 Feb 2024 from crisil
- Rating update · 27 Feb 2023 from crisil
- Rating update · 8 Dec 2022 from crisil
Documents open at BSE or the rating agency that issued them.
Sourced from the company's NSE XBRL filing dated 6 Nov 2026 (unaudited). View the source filing. Figures are as filed and are not investment advice.
Poly Medicure: common questions
Answered from the figures on this page.